CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79

Q: How many CYTOKINETICS (CYTK) shares does Sung Lee hold after the transactions?

After the reported transactions, Sung Lee directly holds 63,221 shares of CYTOKINETICS common stock. This figure comes from the post-transaction ownership reported for the open-market sale entry in the Form 4, showing his continuing equity position in the company.

Q: What options did CYTOKINETICS CFO Sung Lee exercise in this Form 4?

Sung Lee exercised 1,112 non-qualified stock options , each giving the right to buy one share of CYTOKINETICS common stock at an exercise price of $48.51 per share. These options were converted into common shares before the matching open-market sale.

Q: What is the remaining CYTK option position for Sung Lee after these trades?

After the option exercise, Sung Lee has 26,709 non-qualified stock options remaining, each with an exercise price of $48.51 per share and an expiration date of May 30, 2034 , indicating a substantial ongoing derivative-based exposure to CYTOKINETICS stock.

Q: Was the CYTK insider transaction a buy or a sell overall?

The filing combines an exercise of stock options with an open-market sale of 1,112 shares. The transaction summary reflects a net-sell direction by share count, even though it is structured as an exercise-and-sell sequence on the same day.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC EVP and CFO Sung Lee reported an option exercise and related share sale. Lee exercised non-qualified stock options for 1,112 shares of common stock at $48.51 per share, then sold 1,112 shares in an open-market transaction at $87.79 per share.

Following these transactions, Lee directly holds 63,221 shares of common stock. The filing also shows 26,709 non-qualified stock options remaining outstanding with an exercise price of $48.51 per share and an expiration date of May 30, 2034, indicating a continuing equity stake alongside the sale.

Insider Trade Summary 10b5-1

Net Seller: 1,112 shares ($97,622)

Net Sell 3 txns

Insider Lee Sung

Role EVP, Chief Financial Officer

Sold 1,112 shs ($98K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	1,112	$0.00	--
Exercise	Common Stock	1,112	$48.51	$54K
Sale	Common Stock	1,112	$87.79	$98K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 26,709 shares (Direct, null); Common Stock — 64,333 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 1,112 shares Sale price: $87.79/share Shares after sale: 63,221 shares +4 more

7 metrics

Shares sold 1,112 shares Open-market sale of common stock on 2026-07-01 at $87.79

Sale price $87.79/share Price for 1,112 common shares sold on 2026-07-01

Shares after sale 63,221 shares Direct common stock ownership following reported sale

Options exercised 1,112 options Non-qualified stock options converted into common stock

Option exercise price $48.51/share Exercise price for non-qualified stock options

Remaining options 26,709 options Non-qualified stock options outstanding after exercise

Option expiration May 30, 2034 Expiration date for remaining non-qualified stock options

Key Terms

Non-Qualified Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, derivative security

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:18 PM Accepted by SEC EDGAR 07/02/2026 - 05:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Sung

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		M		1,112	A	$48.51	64,333	D
Common Stock	07/01/2026		S		1,112	D	$87.79	63,221	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$48.51	07/01/2026		M			1,112	06/02/2025	05/30/2034	Common Stock	1,112	$0	26,709	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Lee	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did CYTK EVP and CFO Sung Lee report in this Form 4?

Sung Lee reported exercising 1,112 non-qualified stock options at $48.51 per share and selling 1,112 shares of CYTOKINETICS common stock in an open-market transaction at $87.79 per share, reflecting an exercise-and-sell pattern on the same day.

How many CYTOKINETICS (CYTK) shares does Sung Lee hold after the transactions?

After the reported transactions, Sung Lee directly holds 63,221 shares of CYTOKINETICS common stock. This figure comes from the post-transaction ownership reported for the open-market sale entry in the Form 4, showing his continuing equity position in the company.

What options did CYTOKINETICS CFO Sung Lee exercise in this Form 4?

Sung Lee exercised 1,112 non-qualified stock options, each giving the right to buy one share of CYTOKINETICS common stock at an exercise price of $48.51 per share. These options were converted into common shares before the matching open-market sale.

What is the remaining CYTK option position for Sung Lee after these trades?

After the option exercise, Sung Lee has 26,709 non-qualified stock options remaining, each with an exercise price of $48.51 per share and an expiration date of May 30, 2034, indicating a substantial ongoing derivative-based exposure to CYTOKINETICS stock.

Was the CYTK insider transaction a buy or a sell overall?

The filing combines an exercise of stock options with an open-market sale of 1,112 shares. The transaction summary reflects a net-sell direction by share count, even though it is structured as an exercise-and-sell sequence on the same day.